Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00029030.xml
Journal of Pediatric Neurology 2021; 19(06): 425-427
DOI: 10.1055/s-0040-1721380
DOI: 10.1055/s-0040-1721380
Case Report
Dexmedetomidine Infusion as a Novel Supportive Therapy for Fluphenazine-Induced Neuroleptic Malignant Syndrome in a 10-Year-Old Boy: A Case Report and Review of Literature
Funding None.
Abstract
A 10-year-old male child patient developed symptoms of neuroleptic malignant syndrome (NMS) 1 month following initiation of fluphenazine for behavioral therapeutic management. Dexmedetomidine infusion was able to adequately control the symptoms of NMS with resolution of encephalopathy. This was the first report of novel dexmedetomidine utilization for the treatment of NMS. We suggest using dexmedetomidine as an adjunctive agent to control NMS symptomatology without attendant risk of respiratory depression.
Publication History
Received: 03 October 2020
Accepted: 21 October 2020
Article published online:
18 December 2020
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington, DC: American Psychiatric Association; 2013
- 2 Numa A. Neuroleptic malignant syndrome in children. Med J Aust 1991; 155 (06) 417-419
- 3 Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther 2002; 24 (01) 21-37
- 4 Belvederi Murri M, Guaglianone A, Bugliani M. et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D 2015; 15 (01) 45-62
- 5 Sharma R, Trappler B, Ng YK, Leeman CP. Risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother 1996; 30 (7-8): 775-778
- 6 Zalsman G, Lewis R, Konas S. et al. Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents. Int J Adolesc Med Health 2004; 16 (02) 179-182
- 7 Mané A, Baeza I, Morer A, Lázaro ML, Bernardo M. Neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophrenia. J Child Adolesc Psychopharmacol 2005; 15 (06) 844-845
- 8 Aruna AS, Murungi JH. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. Ann Pharmacother 2005; 39 (06) 1131-1135
- 9 Aboraya A, Schumacher J, Abdalla E. et al. Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. W V Med J 2002; 98 (02) 63-65
- 10 Chungh DS, Kim BN, Cho SC. Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol 2005; 19 (04) 422-425
- 11 Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142 (10) 1137-1145
- 12 Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004; 26 (07) 1105-1108
- 13 Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004; 22 (02) 389-411
- 14 Strawn JR, Keck Jr PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164 (06) 870-876
- 15 Gratz SS, Levinson DF, Simpson GM. The treatment and management of neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16 (04) 425-443
- 16 Balzan MV. The neuroleptic malignant syndrome: a logical approach to the patient with temperature and rigidity. Postgrad Med J 1998; 74 (868) 72-76
- 17 Ty EB, Rothner AD. Neuroleptic malignant syndrome in children and adolescents. J Child Neurol 2001; 16 (03) 157-163
- 18 Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatr 2008; 69 (07) 1157-1165
- 19 Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatr 1989; 146 (06) 717-725
- 20 Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?. Br J Psychiatr 1991; 159: 709-712
- 21 Hammerman S, Lam C, Caroff SN. Neuroleptic malignant syndrome and aripiprazole. J Am Acad Child Adolesc Psychiatry 2006; 45 (06) 639-641
- 22 Walker A, Delle Donne A, Douglas E, Spicer K, Pluim T. Novel use of dexmedetomidine for the treatment of anticholinergic toxidrome. J Med Toxicol 2014; 10 (04) 406-410
- 23 Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs 2015; 75 (10) 1119-1130
- 24 Okabe T, Takeda S, Akada S, Hongo T, Sakamoto A. Postoperative intensive care unit drug fever caused by dexmedetomidine. Anesth Analg 2009; 108 (05) 1589-1591